Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

STRO

Sutro Biopharma Inc

Mar 21 • 04:00PM ET

0.7669

Dollar change -0.0291
Percentage change -3.66	%

Healthcare • Biotechnology • USA • NASD

Peers: ARVN SRRK BCYC ADAP KPTI IMTX PSTX NCNA SYBX ONCT

| Held by: VTI VXF IWM IWN VTWO IBB IWC DFAS VTWV SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.01	Insider Own	9.75%	Shs Outstand	82.53M	Perf Week	-5.33%
Market Cap	64.25M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	0.00%	Shs Float	75.61M	Perf Month	-58.09%
Income	-227.46M	PEG	-	EPS next Q	-0.64	Inst Own	67.82%	Short Float	5.90%	Perf Quarter	-63.31%
Sales	62.04M	P/S	1.04	EPS this Y	30.93%	Inst Trans	1.72%	Short Ratio	3.42	Perf Half Y	-80.58%
Book/sh	0.54	P/B	1.42	EPS next Y	50.11%	ROA	-53.02%	Short Interest	4.46M	Perf Year	-78.40%
Cash/sh	3.78	P/C	0.20	EPS next 5Y	32.32%	ROE	-234.19%	52W Range	0.76 - 6.13	Perf YTD	-58.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-4.05%	ROI	-94.35%	52W High	-87.49%	Beta	1.64
Dividend TTM	-	Quick Ratio	2.60	Sales past 5Y	24.31%	Gross Margin	88.37%	52W Low	0.63%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	2.60	EPS Y/Y TTM	-67.75%	Oper. Margin	-384.34%	RSI (14)	25.01	Volatility	16.15% 11.62%
Employees	338	Debt/Eq	4.57	Sales Y/Y TTM	-59.64%	Profit Margin	-366.62%	Recom	2.36	Target Price	5.12
Option/Short	Yes / Yes	LT Debt/Eq	4.41	EPS Q/Q	-272.39%	Payout	-	Rel Volume	1.36	Prev Close	0.80
Sales Surprise	21.79%	EPS Surprise	0.05%	Sales Q/Q	-86.98%	Earnings	Mar 13 AMC	Avg Volume	1.30M	Price	0.77
SMA20	-39.94%	SMA50	-53.31%	SMA200	-74.36%	Trades		Volume	1,775,925	Change	-3.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-25	Downgrade	Wedbush	Outperform → Neutral	$8 → $2
Mar-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Downgrade	BofA Securities	Buy → Underperform	$11 → $1
May-08-24	Initiated	BofA Securities	Buy	$12
Nov-09-23	Initiated	Deutsche Bank	Buy	$12
Oct-06-23	Initiated	Oppenheimer	Outperform	$10
Mar-21-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$15 → $8
Aug-18-22	Resumed	Wells Fargo	Overweight	$15
Jun-18-21	Initiated	H.C. Wainwright	Buy	$35
Dec-03-20	Initiated	Stifel	Buy	$25
Sep-02-20	Initiated	Jefferies	Buy	$21
Jul-16-20	Initiated	Wells Fargo	Overweight	$18
Jan-13-20	Initiated	SunTrust	Buy	$18
Oct-07-19	Initiated	BTIG Research	Buy	$19
Jul-18-19	Initiated	Deutsche Bank	Buy	$22
Apr-29-19	Initiated	H.C. Wainwright	Buy	$18
Oct-22-18	Initiated	Wedbush	Outperform	$20
Oct-22-18	Initiated	Piper Jaffray	Overweight	$23
Oct-22-18	Initiated	JMP Securities	Mkt Outperform	$28

Show Previous Ratings

Mar-18-25 09:45AM	Reddit initiated, Netflix upgraded: Wall Streets top analyst calls (TipRanks)
Mar-15-25 06:40PM	Sutro Biopharma Presents Data from Dose-Optimization Portion of REFR ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 (GlobeNewswire)
06:40PM	Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 (GlobeNewswire)
09:40AM	Chipotle upgraded, Charter initiated: Wall Streets top analyst calls (TipRanks)
09:20AM	Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler (TipRanks)
03:00PM	Loading…
Mar-14-25 03:00PM	Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com) -35.19%
08:18AM	Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs (GuruFocus.com)
07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
Mar-13-25 07:30PM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.72%
04:07PM	Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
04:05PM	Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline (GlobeNewswire)
Mar-03-25 04:05PM	Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -9.75%
Jan-07-25 04:05PM	Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:00AM	Sutro Biopharma and Boehringer Ingelheim BioXcellence collaboration: Established first-in-class cell-free capabilities at commercial scale (GlobeNewswire)
Dec-10-24 08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRaME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire) -16.37%
08:00AM	Loading…
08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFR ME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire)
Nov-18-24 12:00PM	Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-24 05:40PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.88%
04:30PM	Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Nov-04-24 04:05PM	Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference (GlobeNewswire)
11:03AM	Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children (Clinical Trials Arena)
Nov-01-24 08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire) +9.23%
08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFR ME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire)
Oct-10-24 04:05PM	Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum (GlobeNewswire) +14.50%
Sep-20-24 04:01PM	Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-14-24 03:00AM	Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 (GlobeNewswire)
Sep-11-24 08:00AM	Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 (GlobeNewswire)
Aug-26-24 10:48AM	Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why (Zacks)
Aug-23-24 07:03AM	Sutro Biopharma commences Phase II trial of luvelta for lung cancer (Clinical Trials Arena) +10.11%
08:00AM	Loading…
Aug-22-24 08:00AM	Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	Sutro Biopharma Announces Initiation of REFR ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-13-24 05:45PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.49%
04:30PM	Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Jul-09-24 08:00AM	Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer (GlobeNewswire) +10.53%
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-13-24 09:54PM	STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:38PM	Sutro Biopharma Q1 Loss Widens, Revenue Rises (MT Newswires)
04:30PM	Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
10:00AM	Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-08-24 07:17AM	BofA Securities Starts Sutro Biopharma With Buy Rating (MT Newswires)
Apr-30-24 08:00AM	Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR ME-O1 Trial (GlobeNewswire)
Apr-02-24 06:18AM	Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
01:00AM	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com) +27.83% +17.94%
Mar-25-24 09:53PM	STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:30PM	Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Mar-21-24 09:55AM	Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-28-24 04:36AM	Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains? (Zacks)
Feb-06-24 04:05PM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.37%
Jan-04-24 04:05PM	Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeting ADC (GlobeNewswire) -21.40%
Dec-14-23 04:05PM	Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeted ADC, on January 4, 2024 (GlobeNewswire)
Dec-11-23 04:05PM	Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 (GlobeNewswire)
Dec-04-23 04:05PM	Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire) -7.32%
Nov-21-23 04:05PM	Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer (GlobeNewswire) -5.20%
Nov-13-23 05:12PM	Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +14.49%
04:30PM	Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
08:32AM	Why Sutro Biopharma (STRO) Might Surprise This Earnings Season (Zacks)
Oct-22-23 04:25AM	Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference (GlobeNewswire) -5.84%
Sep-28-23 10:17AM	15 Best U.S. Stocks to Buy Now Under $10 (Insider Monkey) +6.25%
Sep-19-23 08:00AM	Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer (GlobeNewswire)
Aug-30-23 08:00AM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 12:57PM	Ken Fishers 12 New Stock Picks (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-10-23 06:05PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Jul-12-23 12:00PM	All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy (Zacks)
Jun-26-23 08:00AM	Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration (GlobeNewswire)
Jun-21-23 04:22AM	Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jun-03-23 04:00PM	Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 (GlobeNewswire)
May-31-23 08:00AM	Sutro Biopharma to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 09:37AM	Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three years (Simply Wall St.)
May-15-23 09:15AM	Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
May-08-23 08:00AM	Sutro Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 03:52AM	Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
May-02-23 10:02AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
May-01-23 10:01AM	Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +7.51%
Apr-27-23 04:30PM	Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer (GlobeNewswire)
Apr-18-23 01:30PM	Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023 (GlobeNewswire)
Apr-17-23 07:55AM	Investors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) Tunnel (Simply Wall St.) +6.36%
Mar-30-23 06:45PM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.08%
04:30PM	Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Mar-17-23 04:01PM	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-23 09:17AM	Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this year (Simply Wall St.)
Mar-01-23 08:00AM	Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-28-23 08:00AM	Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer (GlobeNewswire)
Feb-17-23 04:01PM	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-27-23 06:31AM	Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%? (Simply Wall St.)
Jan-10-23 09:06AM	Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate (Benzinga) -12.42%
Jan-09-23 04:05PM	Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer (GlobeNewswire)
Jan-06-23 01:48PM	With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners (Simply Wall St.)
Jan-04-23 08:00AM	Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 08:00AM	Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer (GlobeNewswire)
Dec-20-22 04:05PM	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract (GlobeNewswire) -9.49%
Dec-17-22 07:42AM	Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 54% over the last year (Simply Wall St.)
Dec-10-22 10:30AM	Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022 (GlobeNewswire)

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
NEWELL WILLIAM J	CEO	Mar 05 '25	Option Exercise	18,750	299,239	Mar 07 04:14 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 05 '25	Option Exercise	8,750	99,027	Mar 07 04:12 PM
ALBINI EDWARD C	CFO AND SECRETARY	Mar 05 '25	Option Exercise	8,750	135,675	Mar 07 04:11 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 04 '25	Option Exercise	9,125	94,025	Mar 06 04:12 PM
NEWELL WILLIAM J	CEO	Mar 04 '25	Option Exercise	31,125	291,625	Mar 06 04:09 PM
Chung Jane	PRESIDENT AND COO	Mar 04 '25	Option Exercise	7,875	100,642	Mar 06 04:06 PM
ALBINI EDWARD C	CFO AND SECRETARY	Mar 01 '25	Option Exercise	25,125	131,868	Mar 04 06:44 PM
Chung Jane	PRESIDENT AND COO	Mar 01 '25	Option Exercise	31,875	102,217	Mar 04 06:42 PM
FITZPATRICK LINDA A	CHIEF PEOPLE & COMM. OFFICER	Mar 01 '25	Option Exercise	20,275	93,227	Mar 04 06:40 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Mar 01 '25	Option Exercise	11,250	35,370	Mar 04 06:34 PM
NEWELL WILLIAM J	CEO	Mar 01 '25	Option Exercise	65,500	285,703	Mar 04 06:32 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	Mar 01 '25	Option Exercise	11,375	43,105	Mar 04 05:58 PM
Borgman Anne Elizabeth	CHIEF MEDICAL OFFICER	Mar 01 '25	Option Exercise	11,250	57,719	Mar 04 05:57 PM
Borgman Anne Elizabeth	CHIEF MEDICAL OFFICER	Feb 28 '25	Option Exercise	37,500	61,874	Mar 04 05:57 PM
Chung Jane	PRESIDENT AND COO	Dec 01 '24	Option Exercise	25,000	79,262	Dec 03 04:09 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Sep 18 '24	Option Exercise	37,500	37,500	Sep 20 04:09 PM
Chung Jane	PRESIDENT AND COO	Aug 09 '24	Option Exercise	18,750	60,951	Aug 13 04:16 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	May 01 '24	Option Exercise	2,500	32,622	May 03 04:21 PM
Srinivasan Venkatesh	CHIEF TECH OP OFFICER	Apr 11 '24	Option Exercise	21,250	37,704	Apr 12 05:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STRO

Sutro Biopharma Inc

Upgrade your FINVIZ experience